Publications Database

Latest additions:
2026-01-08
14:52
OpenAccess [DZNE-2026-00045] Abstract/Journal Article
; ; ; et al
AI Superresolution: Converting T1‐weighted MRI from 3T to 7T resolution toward enhanced imaging biomarkers for Alzheimer's disease
Alzheimer’s Association International Conference, AAIC 25, TorontoToronto, Canada, 27 Jul 2025 - 31 Jul 20252025-07-272025-07-31 Alzheimer's and dementia 21(S2), e106600 () [10.1002/alz70856_106600]
Background:High-resolution (7T) MRI facilitates in vivo imaging of fine anatomical structures selectively affected in Alzheimer's disease (AD), including medial temporal lobe subregions. However, 7T data is challenging to acquire and largely unavailable in clinical settings. [...]
OpenAccess: Download fulltextPDF Download fulltextPDF (PDFA);

Detailed record - Similar records
2026-01-08
14:50
OpenAccess [DZNE-2026-00044] Abstract/Journal Article
; ; ; et al
Nucleus Basalis of Meynert: Functional Connectivity and Morphometry in Alzheimer's Disease and Frontotemporal Dementia
Alzheimer’s Association International Conference, AAIC 25, TorontoToronto, Canada, 27 Jul 2025 - 31 Jul 20252025-07-272025-07-31 Alzheimer's and dementia 21(S2), e105620 () [10.1002/alz70856_105620]
The nucleus basalis of Meynert (NBM) is crucial for learning, attention, and memory. While its involvement in Alzheimer's disease (AD) has been widely reported, the role in frontotemporal dementia (FTD) remains unclear. [...]
OpenAccess: Download fulltextPDF Download fulltextPDF (PDFA);

Detailed record - Similar records
2026-01-08
14:47
OpenAccess [DZNE-2026-00043] Abstract/Journal Article
; ; ; et al
Early changes in basal forebrain volume and cognitive function in preclinical autosomal dominant Alzheimer's disease
Alzheimer’s Association International Conference, AAIC 25, TorontoToronto, Canada, 27 Jul 2025 - 31 Jul 20252025-07-272025-07-31 Alzheimer's and dementia 21(S2), e105027 () [10.1002/alz70856_105027]
Background: The basal forebrain (BF), home to cholinergic neurons essential for attention and memory undergoes structural changes in sporadic Alzheimer's Disease and in at-risk individuals, contributing to cognitive decline. To investigate whether BF volume is reduced in preclinical autosomal-dominant Alzheimer's disease (ADAD), we studied cognitively-unimpaired carriers of the PSEN1 E280A mutation from the Colombian kindred, the largest ADAD cohort with a single mutation, known for early cognitive decline (mild cognitive impairment at age 44, dementia at 49). [...]
OpenAccess: Download fulltextPDF Download fulltextPDF (PDFA);

Detailed record - Similar records
2026-01-08
14:46
OpenAccess [DZNE-2026-00042] Abstract/Journal Article
; ; ; et al
Plasma p ‐tau 217 as a suitable biomarker for monitoring cognitive changes in Alzheimer's disease
Alzheimer’s Association International Conference, AAIC 25, TorontoToronto, Canada, 27 Jul 2025 - 31 Jul 20252025-07-272025-07-31 Alzheimer's and dementia 21(S2), e104771 () [10.1002/alz70856_104771]
With the approval of anti-amyloid therapies in Alzheimer's disease (AD), surrogate biomarkers are urgently needed to monitor treatment effects that translate into clinical benefits. Candidate biomarkers, including amyloid-PET, tau-PET, plasma phosphorylated tau (p-tau), and MRI-assessed atrophy, capture core pathophysiological changes in AD. [...]
OpenAccess: Download fulltextPDF Download fulltextPDF (PDFA);

Detailed record - Similar records
2026-01-08
14:44
OpenAccess [DZNE-2026-00041] Abstract/Journal Article
; ; ; et al
Multi‐tracer PET monitoring of an immunomodulatory therapy in 4R tauopathy: Evaluating a novel drug's impact on glial function and protein pathology
Alzheimer’s Association International Conference, AAIC 25, TorontoToronto, Canada, 27 Jul 2025 - 31 Jul 20252025-07-272025-07-31 Alzheimer's and dementia 21(S2), e104796 () [10.1002/alz70856_104796]
The prevalence of neurodegenerative diseases (ND), including Alzheimer's disease (AD) and non-AD tauopathies, is projected to rise significantly by 2050 due to an aging global population. Chronic neuroinflammation, driven by glial activation in response to protein pathologies, is a major contributor to disease progression. [...]
OpenAccess: Download fulltextPDF Download fulltextPDF (PDFA);

Detailed record - Similar records
2026-01-07
16:33
OpenAccess [DZNE-2026-00040] Journal Article
; ; ; et al
Integrating simulated and experimental data to identify mitochondrial bioenergetic defects in Parkinson's Disease models.
PLOS ONE 21(1), e0339326 () [10.1371/journal.pone.0339326]
Mitochondrial bioenergetics are vital for ATP production and are associated with several diseases, including Parkinson's Disease (PD). Here, we simulated a computational model of mitochondrial ATP production to interrogate mitochondrial bioenergetics under physiological and pathophysiological conditions, and provide a data resource that can be used to interpret mitochondrial bioenergetics experiments. [...]
OpenAccess: Download fulltextPDF Download fulltextPDF (PDFA);

Detailed record - Similar records
2026-01-07
16:30
[DZNE-2026-00039] Journal Article
; ; ; et al
Polygenic risk for psychiatric disorders and its association with neuropsychiatric symptoms in dementia.
Neuropsychiatric symptoms are common in Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD), yet their genetic underpinnings remain unclear. To gain insight into biological processes related to neuropsychiatric symptoms in dementia, we investigated whether polygenic risk scores (PRS) for psychiatric disorders - major depressive disorder (MDD), schizophrenia (SCZ), bipolar disorder (BD), and autism spectrum disorder (ASD) - are associated with neuropsychiatric symptoms in dementia. [...]
Restricted: Download fulltextPDF Download fulltextPDF (PDFA);

Detailed record - Similar records
2026-01-07
16:14
OpenAccess [DZNE-2026-00038] Journal Article
; ; ; et al
Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease: a randomized double-blind prospective study.
Parkinson's disease is associated with a dysbiotic, proinflammatory gut microbiome, disruptions to intestinal barrier functions, and immunological imbalance. Microbiota-produced short-chain fatty acids, such as propionic and butyric acid promote gut barrier integrity and immune regulation, but their impact on Parkinson's disease pathology remains mostly unknown.In a randomized double-blind prospective study, 72 people with Parkinson's disease received propionic and butyric acid and/or the prebiotic fiber 2'-fucosyllactose supplementation over 6 months in combination with existing Parkinson's disease-specific therapy. [...]

Detailed record - Similar records
2026-01-07
16:12

Detailed record - Similar records
2026-01-07
15:47
OpenAccess [DZNE-2026-00036] Abstract/Journal Article
; ; ; et al
Developing a Novel Reference Region for PI‐2620‐PET Imaging to Facilitate Assessment of 4‐Repeat Tauopathies
Alzheimer’s Association International Conference, AAIC 25, TorontoToronto, Canada, 27 Jul 2025 - 31 Jul 20252025-07-272025-07-31 Alzheimer's and dementia 21(S2), e104777 () [10.1002/alz70856_104777]
Neurodegenerative 4-repeat (4R) tauopathies commonly manifest as progressive supranuclear palsy (PSP). PSP patients show elevated PI-2620-PET in subcortical 4R tau predilection sites (e.g., globus pallidus), suggesting PI-2620-PET as a promising 4R tau neuroimaging candidate. [...]
OpenAccess: Download fulltextPDF Download fulltextPDF (PDFA);

Detailed record - Similar records